AMNEAL PHARMACEUTICALS, INC. Impairment of Intangible Assets, Finite-lived
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Impairment of Intangible Assets, Finite-lived of $0 for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2023-11-09
- AMNEAL PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for the quarter ending 2022-12-31 was $18.30M, a 16.82% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for the quarter ending 2022-09-30 was $700.00K, a 75.00% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for the quarter ending 2021-12-31 was $22.00M, a 1592.31% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for fiscal 2022 was $24.10M, a 2.99% increase from fiscal 2021.
- AMNEAL PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for fiscal 2021 was $23.40M, a 37.27% decline from fiscal 2020.
- AMNEAL PHARMACEUTICALS, INC. impairment of intangible assets, finite-lived for fiscal 2020 was $37.30M.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month | Impairment of Intangible Assets, Finite-lived 12 month as first filed |
|---|---|---|---|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $0.00 10-Q · filed 2023-11-09 | ||||
| 2022-12-31 | $18.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $19.00M derived: sum of 2 quarters · filed 2023-11-09 | $24.10M 10-K · filed 2023-03-03 | ||
| 2022-09-30 | $700.00K 10-Q · filed 2023-11-09 | $5.80M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $22.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $22.40M derived: sum of 2 quarters · filed 2023-03-03 | $23.40M derived: sum of 3 quarters · filed 2023-03-03 | $23.40M 10-K · filed 2023-03-03 | $17.70M 10-K · filed 2022-03-01 |
| 2021-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $1.40M derived: sum of 2 quarters · filed 2022-11-07 | $1.40M 10-Q · filed 2022-11-07 | $2.70M derived: sum of 4 quarters · filed 2023-03-03 | |
| 2021-06-30 | $1.00M 10-Q · filed 2021-08-09 | $1.00M 10-Q · filed 2021-08-09 | $2.30M derived: sum of 3 quarters · filed 2023-03-03 | $34.30M derived: sum of 4 quarters · filed 2023-03-03 | |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | $1.30M derived: sum of 2 quarters · filed 2023-03-03 | $33.30M derived: sum of 3 quarters · filed 2023-03-03 | $34.30M derived: sum of 4 quarters · filed 2023-03-03 | |
| 2020-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $33.30M derived: sum of 2 quarters · filed 2023-03-03 | $34.30M derived: sum of 3 quarters · filed 2023-03-03 | $37.30M 10-K · filed 2023-03-03 | |
| 2020-09-30 | $32.00M 10-Q · filed 2020-11-06 | $33.00M derived: sum of 2 quarters · filed 2021-08-09 | $36.00M 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $1.00M 10-Q · filed 2021-08-09 | $3.00M 10-Q · filed 2021-08-09 | |||
| 2019-03-31 | $76.00M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |